RE:RE:Ixinity replacement therapy FDA-approved gene therapies
In November 2022, the Food and Drug Administration approved Hemgenix, CSL Behring's hemophilia B gene therapy. Researchers at Children’s Hospital of Philadelphia are working on other types of gene therapies for hemophilia B with the goal of advancing treatment options for hemophilia B.